PKR Inhibition for Treating Neurodegenerative Diseases
Company Founded Year
Company Number of Employees
NeuroPharmacology | NeuroBioTechnology
Biotechnology & Biopharmaceutical
Medical use (pharma, nerve damage rehabilitation, neurodiagnostics. inc. early diagnosis)
Biochemical: pharmacological drugs (Developing drugs)
Protekt Therapeutics is a biopharmaceutical company aiming to identify and develop a potent and selective oral PKR inhibitor (PKRi) to treat cognitive disorders such as Alzheimerâ€™s disease and mild cognitive impairment. PKR is a stress and proapoptotic kinase that phosphorylates eIF2Î±, a key protein in the translation machinery, and results in inhibition of protein synthesis and impaired memory consolidation.
PKR is also activated during apoptosis, autophagy, neuroinflammation, and AÎ² peptide toxicity, which are prominent features of Alzheimerâ€™s Disease (AD). Therefore, PKR inhibition offers a novel and promising disease-modifying mechanism for modulating multiple key processes in AD and other neurodegenerative diseases.
Protekt Therapeutics was established in the FutuRx Incubator in December 2015.